ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 3.25 | 0.20 | 0.21 |
| FCF Yield | 0.03% | -1.34% | -7.44% | -4.81% |
| EV / EBITDA | 122.49 | -2,397.42 | -21.28 | -18.42 |
| Quality | ||||
| ROIC | 3.92% | -0.67% | -21.96% | -25.76% |
| Gross Margin | 98.10% | 98.91% | 98.74% | 99.57% |
| Cash Conversion Ratio | 0.09 | 15.71 | 1.80 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.09% | 11.53% | -3.63% | -6.32% |
| Free Cash Flow Growth | 102.12% | 9.62% | -22.30% | 6.73% |
| Safety | ||||
| Net Debt / EBITDA | -17.17 | 268.11 | 4.93 | 4.81 |
| Interest Coverage | 24.63 | -3.88 | -49.70 | -61.34 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.28 | 1.02 | -0.01 |
| Cash Conversion Cycle | -704.75 | -1,419.19 | -4,493.71 | -37,973.42 |